Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at firstname.lastname@example.org. Follow @suzannewriter on Twitter.
Articles by Suzanne Elvidge
The International Diagnostics Centre (IDC) is launched at the U.K.'s London School of Hygiene & Tropical Medicine.
A combination of biomarkers and imaging could tag chemotherapy-induced heart damage early on, cutting long-term heart risk in cancer survivors, according to a study reported at the recent San Antonio Breast Cancer Symposium.
Mutations in a pair of genes in the most aggressive form of the childhood cancer neuroblastoma could point the way to new therapies, according to research just published in Nature Genetics.
Biomarkers play a major role in personalized medicine, supporting diagnosis and identifying those patients who are (or aren't) likely to respond, and supporting drugs through clinical trials.
A collaboration between the East and the West is using biomarkers to develop a point of care device that could diagnose traumatic brain injury at the site of the accident, helping doctors make the right decisions for treating the patient.
In a collaboration between Arizona State University, the Biodesign Institute, and Phoenix Children's Hospital, three researchers hope to understand more about desmoplastic small round cell tumor (DSRCT).
A gene change may explain why some newborn babies struggle for breath, and could lead to genetic biomarker-based tests to warn of the risk.
Researchers at the MD Anderson Cancer Center have found a protein, PKM2, that could act as a biomarker in patients with glioblastoma multiforme and have found a new role for a type of kinase inhibitor not tested in this condition so far.
A $3 million grant will fund U.S. researchers in their hunt for markers to track the progress of treatment of Chagas' disease.
Drug resistance can be a problem with lung cancer chemotherapy with Pfizer's Xalkori (crizotinib), and a genetic biomarker published in Cell could help to find the patients most likely to stop responding to the drug, helping doctors to personalize treatment.